graph EGM comparisons
atezolizumab plus bevacizumabtitleatezolizumab alonetitlenivolumab plus ipilimumabtitleavelumab plus axitinibtitlenivolumab alonetitlepembrolizumab alonetitlenivolumab plus cabozantinibtitlepembrolizumab plus lenvatinibtitlepembrolizumab plus axitinibtitleplacebotitlesunitinibtitleeverolimustitleIMmotion-010, 2017 NCT03024996 metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) -9/-9CheckMate 914, 2017 NCT03138512 metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) -9/-9KEYNOTE-564, 0 NCT03142334 metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) 496/498IMmotion-150 (At - all population), 2018 NCT01984242 metastatic/advanced RCC (mRCC) - 1st line (L1) 103/101IMmotion-150 (AtB - all population), 2018 NCT01984242 metastatic/advanced RCC (mRCC) - 1st line (L1) 101/101IMmotion-151 (all population), 2019 NCT02420821 metastatic/advanced RCC (mRCC) - 1st line (L1) 454/461JAVELIN Renal 101 (all population), 2019 NCT02684006 metastatic/advanced RCC (mRCC) - 1st line (L1) 442/444CheckMate 9ER, 2021 NCT03141177 metastatic/advanced RCC (mRCC) - 1st line (L1) 323/328CheckMate 214 (intermediate and poor risk), 2017 NCT02231749 metastatic/advanced RCC (mRCC) - 1st line (L1) 425/422CheckMate 214 (favorable risk) EXPLORATORY, 2017 NCT02231749 metastatic/advanced RCC (mRCC) - 1st line (L1) 125/124CheckMate 214 (all population), 2017 NCT02231749 metastatic/advanced RCC (mRCC) - 1st line (L1) 550/546KEYNOTE-426, 2019 NCT02853331 metastatic/advanced RCC (mRCC) - 1st line (L1) 432/429KEYNOTE-581/CLEAR (PDL1), 2021 NCT02811861 metastatic/advanced RCC (mRCC) - 1st line (L1) 355/357CheckMate 025, 2015 NCT01668784 metastatic/advanced RCC (mRCC) - 2nd line (L2) 410/411IMmotion-151 (PDL1 <1%) EXPLORATORY, 2019 NCT02420821 mRCC - L1 - PDL1 negative 276/277IMmotion-150 (At - PDL1>1%), 2018 NCT01984242 mRCC - L1 - PDL1 positive 54/60IMmotion-150 (AtB - PDL1>1%), 2018 NCT01984242 mRCC - L1 - PDL1 positive 50/60IMmotion-151 (PDL1 >1%), 2019 NCT02420821 mRCC - L1 - PDL1 positive 178/184JAVELIN Renal 101( PDL1>1%), 2019 NCT02684006 mRCC - L1 - PDL1 positive 270/290

Pathology:  metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA);   metastatic/advanced RCC (mRCC) - 1st line (L1);   metastatic/advanced RCC (mRCC) - 2nd line (L2);   mRCC - L1 - PDL1 negative;   mRCC - L1 - PDL1 positive; 

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)metastatic/advanced RCC (mRCC) - 1st line (L1)metastatic/advanced RCC (mRCC) - 2nd line (L2)mRCC - L1 - PDL1 negativemRCC - L1 - PDL1 positive
IMmotion-010, 2017CheckMate 914, 2017KEYNOTE-564, 0IMmotion-150 (At - all population), 2018IMmotion-150 (AtB - all population), 2018IMmotion-151 (all population), 2019JAVELIN Renal 101 (all population), 2019CheckMate 9ER, 2021CheckMate 214 (intermediate and poor risk), 2017CheckMate 214 (favorable risk) EXPLORATORY, 2017CheckMate 214 (all population), 2017KEYNOTE-426, 2019KEYNOTE-581/CLEAR (PDL1), 2021CheckMate 025, 2015IMmotion-151 (PDL1 <1%) EXPLORATORY, 2019IMmotion-150 (At - PDL1>1%), 2018IMmotion-150 (AtB - PDL1>1%), 2018IMmotion-151 (PDL1 >1%), 2019JAVELIN Renal 101( PDL1>1%), 2019
atezolizumab plus bevacizumab5T1T1T1T1T1
atezolizumab alone3T1T1T1
nivolumab plus ipilimumab3T0T1T1T1
avelumab plus axitinib2T1T1
nivolumab alone2T1T1
pembrolizumab alone1T1
nivolumab plus cabozantinib1T1
pembrolizumab plus lenvatinib1T1
pembrolizumab plus axitinib1T1
placebo0T0T0
sunitinib0T0T0T0T0T0T0T0T0T0T0T0T0T0T0T0
everolimus0T0